title: Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?
abstract: Sixty three patients aged 27-66 years (median 52) were allografted from HLA-matched sibling (n=47), 10 of 10 allele-matched unrelated (n=19), or one-antigen/allele-mismatched (n=7) donors aged 24-69 years (median 46) after a conditioning regimen comprising 100 mg/m(2) melphalan. Cyclophosphamide (50 mg/kg) was also administered to patients who had not been autografted previously. Cyclosporine or tacrolimus, and mycophenolate mofetil were administered to prevent graft-versus-host disease (GVHD). The 2-year cumulative incidences of relapse and TRM were 55 and 24% respectively, and 2-year probabilities of overall survival (OS) and disease-free survival (DFS) were 36 and 21%, respectively. Poor performance status, donor age >45 years and elevated lactate dehydrogenase (LDH) increased the risk of treatment-related mortality (TRM), refractory disease and donor age >45 years increased the risk of relapse, and OS and DFS were adversely influenced by refractory disease, poor performance status, increased LDH, and donor age >45 years. Our data suggest that younger donor age is associated with better outcome after sub-myeloablative allogeneic hematopoietic stem cell transplantation (HSCT) for hematologic malignancies due to lower TRM and relapse. This finding raises the question of whether a young 10-allele-matched unrelated donor is superior to an older matched sibling donor in patients where the clinical situation permits a choice between such donors.
authors.affiliation: The Feinberg School of Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA. j-mehta@northwestern.edu
authors.forename: J
authors.initials: J
authors.lastname: Mehta
authors.forename: L I
authors.initials: LI
authors.lastname: Gordon
authors.forename: M S
authors.initials: MS
authors.lastname: Tallman
authors.forename: J N
authors.initials: JN
authors.lastname: Winter
authors.forename: A M
authors.initials: AM
authors.lastname: Evens
authors.forename: A O
authors.initials: AO
authors.lastname: Evens
authors.forename: O
authors.initials: O
authors.lastname: Frankfurt
authors.forename: S F
authors.initials: SF
authors.lastname: Williams
authors.forename: D
authors.initials: D
authors.lastname: Grinblatt
authors.forename: L
authors.initials: L
authors.lastname: Kaminer
authors.forename: R
authors.initials: R
authors.lastname: Meagher
authors.forename: S
authors.initials: S
authors.lastname: Singhal
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000704:Analysis of Variance; D018572:Disease-Free Survival; D005260:Female; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000150:complications; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D012307:Risk Factors; D035781:Siblings; D015996:Survival Rate; D014184:Transplantation, Homologous; D016896:Treatment Outcome